Avalon Pharma Contract Sign Off With Bio-Thera Solutions

About this update from Middle East Pharmaceutical Industries Company

Middle East Pharmaceutical Industries Company SJSC TADAWUL:4016:AVALON PHARMA - CONTRACT SIGN OFF WITH BIO-THERA SOLUTIONSAVALON PHARMA - CONTRACT VALUE REPRESENTS ABOVE 5% OF CO’S REVENUESAVALON PHARMA - 2030 ONWARDS, ESTIMATING INCREMENTAL REVENUE OF AT LEAST 500 MN SAR DURING CONTRACT PERIODAVALON PHARMA- CONTRACT FOR EXCLUSIVE LICENSE TO REGISTER ,COMMERCIALIZE PEMBROLIZUMAB IN SAUDI, MENA MARKETS

View stock analysis, news, and events for Middle East Pharmaceutical Industries Company